Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01303965
What this trial is testing

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Sherif S. Farag 14
Not applicableStudy completedNCT07528911
What this trial is testing

Elements of Adaptive Immunity in Epithelial Ovarian Cancer

Who this might be right for
Epithelial High Grade Serous Ovarian Cancer
Hellenic Cooperative Oncology Group 687
Testing effectiveness (Phase 2)Study completedNCT02308280
What this trial is testing

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaHigh-Risk Cancer
Maisonneuve-Rosemont Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01484275
What this trial is testing

Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Who this might be right for
High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC 85
Testing effectiveness (Phase 2)WithdrawnNCT03003728
What this trial is testing

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Who this might be right for
Multiple Myeloma
University of Arkansas
Large-scale testing (Phase 3)Active Not RecruitingNCT01169337
What this trial is testing

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Who this might be right for
Light Chain Deposition DiseaseSmoldering Multiple Myeloma
National Cancer Institute (NCI) 226
Testing effectiveness (Phase 2)UnknownNCT03188172
What this trial is testing

MUK Nine b: OPTIMUM Treatment Protocol

Who this might be right for
Multiple Myeloma
University of Leeds 95
Testing effectiveness (Phase 2)Study completedNCT00002510
What this trial is testing

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Temple University
Large-scale testing (Phase 3)Study completedNCT01090089
What this trial is testing

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 348
Early research (Phase 1)WithdrawnNCT04579523
What this trial is testing

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Who this might be right for
Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT01118013
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Who this might be right for
LeukemiaLymphomaLymphoproliferative Disorder+3 more
Alliance for Clinical Trials in Oncology 6
Large-scale testing (Phase 3)Study completedNCT01191060
What this trial is testing

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

Who this might be right for
Myeloma
University Hospital, Toulouse 700
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT05767359
What this trial is testing

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Study completedNCT01255514
What this trial is testing

Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Yonsei University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT02544308
What this trial is testing

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Who this might be right for
Plasmacytoma
University College, London 36
Early research (Phase 1)Study completedNCT02043847
What this trial is testing

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma, Refractory to Standard Treatment
University of Illinois at Chicago 12
Testing effectiveness (Phase 2)Study completedNCT00970021
What this trial is testing

Agaricus Blazei Murill in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Ullevaal University Hospital 39
Testing effectiveness (Phase 2)UnknownNCT00397800
What this trial is testing

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Technical University of Munich 12
Testing effectiveness (Phase 2)Looking for participantsNCT05469893
What this trial is testing

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
High-risk Smoldering Multiple MyelomaSmoldering Multiple MyelomaMultiple Myeloma
Irene Ghobrial, MD 52
Next Page